These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Nanomedicines Lost in Translation. Guidolin K; Zheng G ACS Nano; 2019 Dec; 13(12):13620-13626. PubMed ID: 31800203 [TBL] [Abstract][Full Text] [Related]
7. Towards tailored management of malignant brain tumors with nanotheranostics. Aparicio-Blanco J; Torres-Suárez AI Acta Biomater; 2018 Jun; 73():52-63. PubMed ID: 29678675 [TBL] [Abstract][Full Text] [Related]
8. Membrane-encapsulated camouflaged nanomedicines in drug delivery. Ghosh S; Girigoswami K; Girigoswami A Nanomedicine (Lond); 2019 Aug; 14(15):2067-2082. PubMed ID: 31355709 [TBL] [Abstract][Full Text] [Related]
9. Chemically Modified Natural Polymer-Based Theranostic Nanomedicines: Are They the Golden Gate toward a Jaymand M ACS Biomater Sci Eng; 2020 Jan; 6(1):134-166. PubMed ID: 33463213 [TBL] [Abstract][Full Text] [Related]
10. Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine. Farolfi A; Ghedini P; Fanti S Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):217-223. PubMed ID: 30267115 [TBL] [Abstract][Full Text] [Related]
11. The 2019 SLAS Technology Ten: Translating Life Sciences Innovation. Chow EK SLAS Technol; 2019 Feb; 24(1):66-69. PubMed ID: 30798677 [No Abstract] [Full Text] [Related]
12. Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. Singh OP; Gedda MR; Mudavath SL; Srivastava ON; Sundar S Nanomedicine (Lond); 2019 Jul; 14(14):1911-1927. PubMed ID: 31313971 [TBL] [Abstract][Full Text] [Related]
13. Exosome Theranostics: Biology and Translational Medicine. He C; Zheng S; Luo Y; Wang B Theranostics; 2018; 8(1):237-255. PubMed ID: 29290805 [TBL] [Abstract][Full Text] [Related]
14. Exogenous/Endogenous-Triggered Mesoporous Silica Cancer Nanomedicine. Yang B; Chen Y; Shi J Adv Healthc Mater; 2018 Oct; 7(20):e1800268. PubMed ID: 29938917 [TBL] [Abstract][Full Text] [Related]
15. Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines. Stéen EJL; Edem PE; Nørregaard K; Jørgensen JT; Shalgunov V; Kjaer A; Herth MM Biomaterials; 2018 Oct; 179():209-245. PubMed ID: 30007471 [TBL] [Abstract][Full Text] [Related]
16. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting. Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459 [TBL] [Abstract][Full Text] [Related]
17. Q&A: Omid Farokhzad on Nanomedicine in Cancer. Cancer Discov; 2016 Dec; 6(12):1300. PubMed ID: 27815294 [TBL] [Abstract][Full Text] [Related]
18. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines. Durymanov MO; Rosenkranz AA; Sobolev AS Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316 [TBL] [Abstract][Full Text] [Related]
19. Supramolecular Nanomedicine - An Overview. Sekhon BS Curr Drug Targets; 2015; 16(13):1407-28. PubMed ID: 25090984 [TBL] [Abstract][Full Text] [Related]
20. Recent Developments of Liposomes as Nanocarriers for Theranostic Applications. Xing H; Hwang K; Lu Y Theranostics; 2016; 6(9):1336-52. PubMed ID: 27375783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]